Saratov JOURNAL of Medical and Scientific Research

polymorphism

Genetic pathogenesis of essential arterial hypertension (the review)

Year: 2011, volume 7 Issue: №1 Pages: 083-087
Heading: Internal Diseases Article type: Review
Authors: Shevchenko O.V., Svistunov А.А., Borodulin V.B., Ruta A.V., Bychkov E.N.
Organization: Saratov State Medical University, First Moscow State Medical University n.a. I.M. Sechenov
Summary:

It is proved that genetic factors may be considered as fundamental in the development of essential arterial hypertension (AH). Important role in this process belongs to the genes whose products are involved in regulating blood pressure - adrenergic, renin-angiotensin-aldosterone, and homocyclic bradykinin systems. These systems are closely connected by serial and parallel chemical reactions that enable to use genetic testing to determine the state of the whole system. Analysis of polymorphic markers of different groups of genes encoding components of the renin-angiotensin-aldosterone system allows to define the role of each of the pathogenic factor of hypertension in the development of the disease

AttachmentSize
201101_083-087.pdf258.4 KB

BETA-ADRENORECEPTORS GENETIC POLYMORPHISM CONNECTION WITH BETA-BLOKER THERAPY EFFICACY IN PATIENTS WITH CARDIOVASCULAR DISORDERS

Year: 2009, volume 5 Issue: №1 Pages: 41-44
Heading: Clinical Pharmacology Article type: Original article
Authors: A.N. Levanov, I.V. Ignatyev, D.A. Sychev, S.I. Bogoslovskaya, A.A. Svistunov
Organization: Saratov State Medical University, First Moscow State Medical University n.a. I.M. Sechenov, Institute of Clinical Pharmacology
Summary:

At present it is obvious that genetic peculiarities of patients are the major reason for individual differences in pharmacological responses to (?-adrenoblockers. Furthermore ADRB1 gene polymorphism is responsible for the efficiency of (?-adrenoblockers. Thus, a real prospect exists for an individualized approach to administration of (?-adrenoblockers and selection of dosage based on patient’s genotype, which must undoubtedly increase efficiency of the administered therapy. Reviewfocuses on gene polymorphism responsible for (?-adrenoblockers pharmacodynamics and on the clinical significance of the polymorphism detection to individualize drug therapy based on patient’s genotype.

AttachmentSize
200901_041_044.pdf207.86 KB